Download PDF

1. Company Snapshot

1.a. Company Description

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage.


Deciphera Pharmaceuticals, Inc.was founded in 2003 and is headquartered in Waltham, Massachusetts.

Show Full description

1.b. Last Insights on DCPH

Deciphera Pharmaceuticals, Inc. (DCPH) experienced a 51.0% performance over the past 3 months, driven by a $2.4 billion acquisition agreement with ONO Pharmaceutical. The company's stock surged 74.3% in a month, with investors reacting positively to the deal. The acquisition is expected to close in the third quarter of 2024, providing a significant premium to shareholders.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting

Dec -06

Source: businesswire.com

Card image cap

Deciphera Announces the Opening of a New Office in Zug, Switzerland

Nov -17

Source: businesswire.com

Card image cap

Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025

Nov -12

Source: businesswire.com

Card image cap

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025

Oct -18

Source: businesswire.com

Card image cap

Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Sep -17

Source: businesswire.com

Card image cap

Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Jul -28

Source: businesswire.com

Card image cap

U.S. FDA Grants Full Approval of Deciphera's ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)

Feb -14

Source: businesswire.com

Card image cap

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Jul -19

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Switch Control Kinase Inhibitor Platform

Expected Growth: 11.3%

Deciphera's Switch Control Kinase Inhibitor Platform growth is driven by increasing adoption in cancer treatment, strong clinical trial results, and expanding pipeline of kinase inhibitors. The platform's unique mechanism of action, targeting specific kinases, addresses unmet needs in cancer therapy. Growing demand for targeted therapies, partnerships, and collaborations also contribute to the 11.3% growth.

7. Detailed Products

Qinlock

Qinlock is an oral kinase inhibitor that targets KIT and PDGFRA mutations, used to treat adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment for this disease.

Ripretinib

Ripretinib is an oral kinase inhibitor that targets KIT and PDGFRA mutations, used to treat adult patients with advanced GIST who have received prior treatment for this disease.

DCC-2618

DCC-2618 is an oral kinase inhibitor that targets KIT and PDGFRA mutations, currently in clinical trials for the treatment of GIST and other solid tumors.

DCC-3116

DCC-3116 is an oral inhibitor of ULK kinase, currently in clinical trials for the treatment of solid tumors.

Rebastinib

Rebastinib is an oral inhibitor of TIE2 kinase, currently in clinical trials for the treatment of solid tumors.

8. Deciphera Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Deciphera Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative cancer treatment options, but the company's focus on kinase inhibitors and precision medicine may provide some differentiation.

Bargaining Power Of Customers

Deciphera Pharmaceuticals, Inc. has a low bargaining power of customers due to the specialized nature of its cancer treatment products and the lack of direct competition.

Bargaining Power Of Suppliers

Deciphera Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and manufacturing services, but the company's reliance on a few key suppliers may limit its negotiating power.

Threat Of New Entrants

Deciphera Pharmaceuticals, Inc. faces a high threat of new entrants due to the attractiveness of the oncology market and the presence of many biotech companies and research institutions working on cancer treatments.

Intensity Of Rivalry

Deciphera Pharmaceuticals, Inc. operates in a highly competitive oncology market with many established players and a high level of R&D investment, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 6.87%
Debt Cost 3.95%
Equity Weight 93.13%
Equity Cost 4.94%
WACC 4.87%
Leverage 7.37%

11. Quality Control: Deciphera Pharmaceuticals, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Intra-Cellular Therapies

A-Score: 5.3/10

Value: 6.0

Growth: 7.1

Quality: 5.1

Yield: 0.0

Momentum: 10.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Elanco Animal Health

A-Score: 4.6/10

Value: 3.9

Growth: 6.0

Quality: 5.1

Yield: 0.0

Momentum: 8.5

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Amneal Pharmaceuticals

A-Score: 4.4/10

Value: 3.9

Growth: 3.7

Quality: 6.0

Yield: 0.0

Momentum: 7.5

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Lantheus Holdings

A-Score: 4.2/10

Value: 5.8

Growth: 9.0

Quality: 7.9

Yield: 0.0

Momentum: 0.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Deciphera Pharmaceuticals

A-Score: 3.9/10

Value: 6.2

Growth: 6.1

Quality: 5.0

Yield: 0.0

Momentum: 5.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Catalent

A-Score: 3.0/10

Value: 3.2

Growth: 2.2

Quality: 1.8

Yield: 0.0

Momentum: 6.0

Volatility: 5.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

25.59$

Current Price

25.59$

Potential

-0.00%

Expected Cash-Flows